Relax Those Sore Muscles With the Insignia 2D Zero Gravity Massage Chair at a $1,200 Discount
If your body feels sore and stiff at the end of the day and you've been searching for a way to unwind with a spa-like experience without leaving your home, a massage chair might be just the thing. These chairs aren't the most popular option, mostly because of their hefty price tag, but right now you can score one at a serious discount.
Best Buy is currently offering a massive $1,200 off the Insignia 2D zero gravity full body massage chair, bringing the price down to $1,300. The deal is available on the black model and we've already seen the discounted price bounce from $800 to $1,200 so this might be your last chance to save this big.
This sophisticated leather chair offers five massage options (kneading, tapping, knocking, shiatsu, and kneading and tapping), as well as six preset programs that target different areas of your body, including neck, shoulders and waist.
The built-in upper body scanner can automatically adjust to your measurements, which means it can personalize the massage to your body type and you won't have a problem sitting comfortably for extended periods. This also makes it effective for just about anyone in the household.
Hey, did you know? CNET Deals texts are free, easy and save you money.
If you deal with sore muscles often, you'll also appreciate the infrared heat therapy designed to instantly soothe and relax. Plus, you don't always have to sit upright. The massage chair offers three preset reclining positions that elevate your legs and reduce strain on your spine. If none of those suit you, you can also manually position it using the included remote.
Why this deal matters
Massage chairs with multiple features typically run well over $2,000, especially those with full-body coverage and smart functions. Right now, the Insignia 2D zero gravity massage chair is $1,200 off, and while $1,300 still isn't exactly cheap, it's a solid opportunity to invest in your well-being without paying full price.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
A new weight-loss treatment that can be administered as either a weekly injection or a daily pill has shown promising results in early-stage trials, according to a new study. In one of the trials, 125 adults were assigned to weekly injections of amycretin. Those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost 15 per cent of their body weight over a longer 68 week period. Another trial enrolled 144 adults to test the pill version of amycretin. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. While jabs like Ozempic, Wegovy and Mounjaro only target the body's GLP-1 receptors, amycretin targets them as well as the amylin receptors, which help regulate blood glucose levels and appetite. The drug helps to prevent overeating and promote feelings of satiety. The findings were published in The Lancet and presented this week at the American Diabetes Association's Scientific Sessions in Chicago. Researchers also reported that the drug appeared to improve participants' blood sugar control, an important marker for those at risk of developing Type 2 diabetes. Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers. Pill formulations may simplify prescribing and make long-term weight-loss support easier to scale up. Unlike drugs like Ozempic, amycretin tablets would not need to be refrigerated and do not require syringes. However, amycretin remains in the early stages of clinical testing and that larger trials will be required to fully establish its safety and efficacy. Both forms of the drug were also associated with improvements in blood sugar levels. Patients did report side effects, including nausea and vomiting, but researchers said that they tended to resolve as the treatment progressed.
Yahoo
an hour ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
Yahoo
an hour ago
- Yahoo
Animals recovering and being adopted after rescue operation
KINGSVILLE — The Ashtabula County Animal Protective League has been taking care of and adopting out many of the animals it took in from two rescue operations that took place last month. The rescue operations occurred during May at two homes in the Ashtabula area and recovered over 70 animals, mostly cats, alongside three dogs. 'Every single animal that came in received a medical exam, and we immediately started treatment on whatever we could,' APL Executive Director Catena Shore said. Many people helped out the animals, she said. 'We have some amazing people who were here literally nursing animals back to health,' Shore said. Shore said many of the animals are doing better. 'The vast majority of them are either completely recuperated, have been spayed or neutered, vaccinated and are up for adoption or already have been adopted out,' she said. Many of the cats have been doing great, Shore said. 'They're beautiful cats,' she said. 'Most of them are really really sweet. They're going really fast, and we're finding really good homes for them, which is really rewarding.' The APL is a no-kill shelter, Shore said. 'We do our best for every single animal that comes in through our doors,' she said. 'We do not euthanize for space.' Shore and other APL staff have been overseeing adoptions at the APL, she said. 'The dogs that came in from that case, two of them were bonded, so we were able to send them together, so they'll stay together,' she said. One of the adopters has been sending pictures to Shore, as the cat has been settling in the home, she said. 'Mind you, this cat came from ... the house, where he could hardly breathe, because there's fecal matter everywhere, so we got him fixed up, and we took him to PetSmart,' she said. 'He got adopted out from there, and he's living his best life right now.' Seeing the cat do better was really rewarding for Shore, she said. 'There's happy stories and situations like that,' she said. The APL accepts monetary donations through its website, Applications for adoption can be found on the APL's website. Charges were filed in Ashtabula Municipal Court related to the case earlier this week. Karen Pierce and Christopher Alexander were charged with 43 counts of cruelty to companion animals in an Ashtabula city case. Pierce was charged with 31 counts of cruelty to companion animals in an Ashtabula Township case.
